Home  |  Contact

Cellosaurus SCaBER (CVCL_3599)

[Text version]

Cell line name SCaBER
Synonyms SCABER; Scaber
Accession CVCL_3599
Resource Identification Initiative To cite this cell line use: SCaBER (RRID:CVCL_3599)
Comments Part of: BLA-40 bladder carcinoma cell line panel.
Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: UBC-40 urothelial bladder cancer cell line index.
Microsatellite instability: Stable (MSS) (Sanger).
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations TERT c.228C>T (-124C>T); in promoter (PubMed=24035680; PubMed=31068700).
Homozygous for TP53 p.Arg110Leu (c.329G>T) (PubMed=9850064; CCLE; Cosmic-CLP).
Genome ancestry Source: PubMed=30894373

Origin% genome
African86.54
Native American1.69
East Asian, North2.11
East Asian, South0
South Asian0
European, North6
European, South3.66
Disease Bladder squamous cell carcinoma (NCIt: C4031)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Age at sampling 58Y
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; PubMed=11416159; PubMed=27270441

Markers:
AmelogeninX,Y
CSF1PO11,13
D5S81812,13
D7S8208,10
D8S117913,14
D13S31711,12
D16S53911,12
D18S5115
D21S1129,32.2
FGA22,23
TH017,9
TPOX9,11
vWA16

Run an STR similarity search on this cell line
Web pages https://www.synapse.org/UC25
http://www.cellresource.cn/fdetail.aspx?id=261
http://www.cellresource.cn/fdetail.aspx?id=644
Publications

PubMed=947851; DOI=10.1002/ijc.2910170604
O'Toole C.M., Nayak S.K., Price Z.H., Gilbert W.H., Waisman J.
A cell line (SCaBER) derived from squamous cell carcinoma of the human urinary bladder.
Int. J. Cancer 17:707-714(1976)

PubMed=571047
Fogh J.
Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors.
Natl. Cancer Inst. Monogr. 49:5-9(1978)

PubMed=6244232
Williams R.D.
Human urologic cancer cell lines.
Invest. Urol. 17:359-363(1980)

PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=6823318; DOI=10.1038/301429a0
O'Toole C.M., Povey S., Hepburn P.J., Franks L.M.
Identity of some human bladder cancer cell lines.
Nature 301:429-430(1983)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=2990217
Yee C., Krishnan-Hewlett I., Baker C.C., Schlegel R., Howley P.M.
Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines.
Am. J. Pathol. 119:361-366(1985)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3708594
Masters J.R.W., Hepburn P.J., Walker L., Highman W.J., Trejdosiewicz L.K., Povey S., Parkar M., Hill B.T., Riddle P.R., Franks L.M.
Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines.
Cancer Res. 46:3630-3636(1986)

PubMed=8873383; DOI=10.1007/BF00295899
Stadler W.M., Olopade O.I.
The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.
Urol. Res. 24:239-244(1996)

PubMed=9850064
Markl I.D.C., Jones P.A.
Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.
Cancer Res. 58:5348-5353(1998)

PubMed=12127398; DOI=10.1016/S0165-4608(01)00648-3
Strefford J.C., Lillington D.M., Steggall M., Lane T.M., Nouri A.M.E., Young B.D., Oliver R.T.D.
Novel chromosome findings in bladder cancer cell lines detected with multiplex fluorescence in situ hybridization.
Cancer Genet. Cytogenet. 135:139-146(2002)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23401075; DOI=10.1002/path.4176
Guo Y., Chekaluk Y., Zhang J., Du J., Gray N.S., Wu C.-L., Kwiatkowski D.J.
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
J. Pathol. 230:17-27(2013)

PubMed=24367658; DOI=10.1371/journal.pone.0084411
Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H., Knowles M.A.
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
PLoS ONE 8:E84411-E84411(2013)

PubMed=24018021; DOI=10.1016/j.eururo.2013.08.052
Allory Y., Beukers W., Sagrera A., Flandez M., Marques M., Marquez M., van der Keur K.A., Dyrskjot L., Lurkin I., Vermeij M., Carrato A., Lloreta J., Lorente J.A., Carrillo-de-Santa-Pau E., Masius R.G., Kogevinas M., Steyerberg E.W., van Tilborg A.A.G., Abas C., Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.
Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Eur. Urol. 65:360-366(2014)

PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057
Hurst C.D., Platt F.M., Knowles M.A.
Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.
Eur. Urol. 65:367-369(2014)

PubMed=25997541; DOI=10.1186/s12864-015-1450-3
Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B., Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G., Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D., Chanock S.J., Valencia A., Real F.X.
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
BMC Genomics 16:403-403(2015)

PubMed=27270441; DOI=10.1038/onc.2016.172
Nickerson M.L., Witte N., Im K.M., Turan S., Owens C., Misner K., Tsang S.X., Cai Z., Wu S., Dean M., Costello J.C., Theodorescu D.
Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.
Oncogene 36:35-46(2017)

PubMed=29732388; DOI=10.3233/BLC-180167
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Bladder Cancer 4:169-183(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

Cross-references
Cell line collections ATCC; HTB-3
Cell line databases/resources CCLE; SCABER_URINARY_TRACT
CCRID; 3111C0001CCC000261
CCRID; 3131C0001000700076
Cell_Model_Passport; SIDM00032
Cosmic-CLP; 1299051
DepMap; ACH-000839
IGRhCellID; SCaBER
LINCS_LDP; LCL-1540
Ontologies BTO; BTO:0003777
CLO; CLO_0008965
EFO; EFO_0002325
Biological sample resources BioSample; SAMN03472741
BioSample; SAMN10988312
Chemistry resources ChEMBL-Cells; CHEMBL3307437
ChEMBL-Targets; CHEMBL614898
GDSC; 1299051
PharmacoDB; SCaBER_1351_2019
Gene expression databases ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM136226
GEO; GSM887557
GEO; GSM888640
GEO; GSM1374862
GEO; GSM1374863
GEO; GSM1574562
GEO; GSM1670407
Other Wikidata; Q54952320
Polymorphism and mutation databases Cosmic; 687456
Cosmic; 715717
Cosmic; 760489
Cosmic; 845570
Cosmic; 923376
Cosmic; 925835
Cosmic; 928824
Cosmic; 943743
Cosmic; 1046689
Cosmic; 1285126
Cosmic; 1286000
Cosmic; 1927304
Cosmic; 1995625
Cosmic; 2037956
Cosmic; 2050461
Cosmic; 2686113
IARC_TP53; 375
LiGeA; CCLE_439
Entry history
Entry creation04-Apr-2012
Last entry updated06-Sep-2019
Version number28